Дисертації з теми "COVID-19 vaccines"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-40 дисертацій для дослідження на тему "COVID-19 vaccines".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте дисертації для різних дисциплін та оформлюйте правильно вашу бібліографію.
Persson, Morgan. "COVID-19 Vaccines : A literature analysis of the three first approved COVID-19 Vaccines in the EU." Thesis, Umeå universitet, Institutionen för integrativ medicinsk biologi (IMB), 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-179341.
Повний текст джерелаSvensson, Adrian. "En jämförelse av olika covid-19 vaccin." Thesis, Malmö universitet, Fakulteten för hälsa och samhälle (HS), 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:mau:diva-44521.
Повний текст джерелаBackground: At the end of 2019, several cases of pneumonia of unknown ethology were discovered in Wuhan, China. After isolating and sequencing the pathogen it became apparent that it was a Coronavirus, named SARS-CoV-2. Social restrictions and mask wearing mandates have not managed to stop this pandemic, and the hope lies with the different vaccine candidates that started to be developed during 2020. Aim: The aim was to compare different vaccines efficacy and prevalence of side effects. Method: A systemic literature study was implemented, the search was done in Pubmed and four papers were selected to compare vaccine efficacy and side effects for the three vaccines that were approved by Läkemedelsverket in February. Results: Pfizer/BioNTech’s mRNA-vaccine showed an efficacy of 94,8%, Moderna’s an efficacy of 94,1% and Oxford-AstraZeneca’s vector vaccine showed an efficacy of 70,4%. The most common side effects following vaccination was pain at the site of injection, headache and fatigue. Conclusion: A satisfying comparison could not be achieved since the different phase III studies were performed on different age groups and in different parts of the world where SARS-CoV-2 mutations differ, which could impact the results.
Polack, Fernando P., Stephen J. Thomas, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, John L. Perez, et al. "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine." Universidad Peruana de Ciencias Aplicadas (UPC), 2020. http://hdl.handle.net/10757/655958.
Повний текст джерелаLindholm, Anton. "VACCINE CITIZENSHIP : Covid-19 vaccination in a semi-rural community of Oaxaca, Mexico." Thesis, Stockholms universitet, Socialantropologiska institutionen, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-195134.
Повний текст джерелаSandaka, Gowtham Kumar, and Bala Namratha Gaekwade. "Sentiment Analysis and Time-series Analysis for the COVID-19 vaccine Tweets." Thesis, Blekinge Tekniska Högskola, Institutionen för datavetenskap, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:bth-21901.
Повний текст джерелаPark, Yhesaem. "An Equitable Framework for Antiretroviral Therapy and COVID-19 Vaccine Allocation Strategies in Botswana." Thesis, Université d'Ottawa / University of Ottawa, 2021. http://hdl.handle.net/10393/42524.
Повний текст джерелаFridlund, Daniel, and Patrik Persson. "Uppfattade risker med covid-19 vaccin -Påverkar solidaritet och förändrad tillit riskuppfattningar?" Thesis, Örebro universitet, Institutionen för humaniora, utbildnings- och samhällsvetenskap, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-92438.
Повний текст джерелаThe ongoing vaccination against covid-19 has meant that many people begin to see the light in the tunnel of the dark time that the corona pandemic has caused. However, there is no consensus about the vaccine as exclusively positive for public health as some instead choose to emphasize the risks that the vaccine may entail over the benefits of vaccination.Previous research shows that factors such as trust, risks and individual medical considerations, as well as cultural aspects, play a crucial role in risk perception regarding vaccination.The theoretical frame of reference in this study is based on Beck’s theory of the risks society, Giddens’ trust in expert systems, and Douglas’ cultural risk theory and blameculture.The aim of this pilot study is to investigate students’ perception of risk regarding the vaccine against covid-19, and whether risk perception is affected by factors such as changes in trust and degree of solidarity.The data collection consists of a quantitative method in the form of a survey, where the study sample consists of members of the group ”Dom kallar oss studenter” on Facebook. Data from the survey were then analyzed by univariate analysis and multivariate regression analyzes.Results from the study show that students with impaired trust in authorities perceive risks of side effects from the vaccine to a greater degree than students who have an equivalent or improved trust in authorities. It also shows that students with a high degree of solidarity see less risks with side effects from the vaccine than those with a low solidarity attitude.
Claesson, Elin, and Gonzalez Esmeralda Patron. "Det virala viruset : En tematisk analys på desinformation om covid-19 vaccinen i svenska facebookgrupper." Thesis, Linnéuniversitetet, Institutionen för medier och journalistik (MJ), 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-104458.
Повний текст джерелаMyhr, Anton. "Attityder och tillit under Coronapandemin : En kvantitativ sociologisk studie om attityd- och tillitsstrukturer kring makthavare, vacciner och Covid-19-pandemin." Thesis, Uppsala universitet, Sociologiska institutionen, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-444251.
Повний текст джерелаGezelius, Rebecka. "Vaccinmotståndet under Covid-19-pandemin : En netnografisk studie av vaccinmotstånd på Flashback forum." Thesis, Luleå tekniska universitet, Institutionen för ekonomi, teknik, konst och samhälle, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:ltu:diva-85687.
Повний текст джерелаThe Covid-19-pandemic, or Coronapandemic as it is popularly called, has affected everyone's livesfor over a year with various restrictions and 3,5 million people have died with the Covid-19-virus.Despite this, many do not want to be vaccinated against Covid-19 now that vaccines have beendeveloped. A survey conducted in January 2021 shows that 63% of Sweden's population want tobe vaccinated against Covid-19. This can be considered unfortunate because the World HealthOrganization listed vaccine resistance as one of ten global health threats in 2019. It is of interestto investigate vaccine resistance during the Covid-19-pandemic as it is a relatively unexploredarea. The purpose of this study is to investigate how vaccination opponents express themselvesabout the Covid-19-vaccines on the internet forum Flashback.This has been investigated through a netnographic qualitative study where the content of 9different threads on Flashback has been studied. The results of the study have been analyzed usingUlrich Beck's concepts of "risk", Anthony Gidden's definition of the terms "trust" and"expertsystem" as well as previous research on vaccine resistance on social media. The results ofthe study indicate that people who were against the Covid-19-vaccine tended to see the vaccine asa major risk. They were afraid of various side effects and they tended to value the vaccine as agreater risk than getting Covid-19. A common trend among vaccine opponents on Flashback wasthat they tended to distrust the science behind vaccines and instead prefered alternative methodsinstead of vaccines. They tended to think that Covid-19 is not a dangerous disease or that the wholedisease is invented by pharmaceutical companies, the media, the authorities and the governmenttogether. Vaccine opponents on Flashback tended to believe that the vaccine against Covid-19 willeither kill or sterilize people to depopulate the planet, or that the drug companies want to makemoney off vaccines. This indicates that vaccine opponents had a lot of mistrust of the Covid-19-vaccine as an expertsystem, but also pharmaceutical companies, the government, authorities and media.
Andersson, Jennifer, and Sue-Ellen Njekwa. "Pandemin är inte över förran den är det överallt : En kvalitativ studie om hur experter ser på distributionen av vaccin mot covid-19 mellan hög- och låginkomstländer." Thesis, Jönköping University, HLK, Globala studier, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:hj:diva-53763.
Повний текст джерелаThe COVID-19 pandemic poses a global threat to health, economic well-being and political sta- bility. According to researchers, COVID-19 vaccines are a key to ending the pandemic and return- ing to a certain type of normality. The issue is that the COVID-19 vaccines have been unevenly distributed between high- and low-income countries. This study is based on qualitative semi-struc- tured interviews exploring how experts view the distribution of the COVID-19 vaccines between high- and low-income countries. More specifically, what factors that they consider to affect the distribution and what measures are needed to make the distribution more equitable. The study connects to the theoretical framework of global justice which is used to clarify why humans have obligations to help each other. The result of the study indicates that the majority of experts con- clude that the distribution of the COVID-19 vaccines has been very uneven because high-income countries have obtained more vaccines than low-income countries. According to experts, an une- ven distribution of the vaccines can lead to several consequences such as the development of mu- tants which the vaccine does not work against, and thus to the pandemic continuing. The main factor pointed out by the experts is that countries have acted nationalistic and that there has been a lot of pressure on political leaders to procure vaccines for their populations. The experts agree that the Covax initiative was a good measure for the vaccines to be distributed more fairly, alt- hough they also highlighted challenges with Covax. This study therefore contributes to the under- standing that there are many factors that affect the global distribution of vaccines against COVID- 19, but also that there are several measures to make the distribution more equitable.
Gustavsson, Fredrik, and Anton Rinaldo. ""Get a better attitude!" : An analysis of media use and support/hesitancy attitudes towards the COVID-19 vaccine." Thesis, Karlstads universitet, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:kau:diva-85224.
Повний текст джерелаDenna studie undersöker förhållandet mellan medieanvändning och förespråkande/tveksamhet mot COVID-19-vaccinet. Syftet med denna studie är att analysera förhållandet mellan sociala medier och traditionell medieanvändning och attityder till förespråkande/tveksamhet gentemot COVID-19-vaccinet. Vi vill analysera hur de sociala och traditionella medierna som nyhetskälla är relaterade till förespråkande och tveksamhet. Vidare vill vi se om medieanvändning som nyhetskälla har något samband med avvägningsinställningen till COVID-19. Vi har hittat ett forsknings hål i COVID-19-pandemin och sambandet mellan social och traditionell medieanvändning som nyhetskälla och förespråkande, tveksamhet och avvägningsattityder till COVID-19-vaccinet. RQ 1: Vad är förhållandet mellan användning av sociala medier som nyhetskälla och förespråkande/tveksamhet mot COVID-19-vaccinet? RQ 2: Vad är förhållandet mellan traditionell medieanvändning som nyhetskälla och förespråkande/tveksamhet mot COVID-19-vaccinet? Metoden för denna studie är en kvantitativ undersökning om medieanvändning före och under COVID-19-pandemin och förespråkande, tveksamhet och avvägning av attityder till COVID-19-vaccinet. Befolkningsstorleken är 201 svenska medborgare i åldrarna 18-65. Urvalet samlades in genom ett snowball sample. Studien har ett teoretiskt ramverk som består av kriskommunikation, misinformation, ekokammare, attityder och social förstärkning av risk. Dessutom presenterar studien tidigare forskning som liknar studien. Den tidigare forskningen presenterar några viktiga resultat, såsom användningen av sociala medier tenderar att öka under kriser, hur ekokammare kan ökas av känslan av rädsla och forskning om attityder till vacciner. Tidigare forskning presenterar också hur misinformation sprids på sociala medier och hur antivaccinationsrörelsen utnyttjar det postmodern health paradigm som får människor att vända sig till internet med sina medicinska problem. Studien drar slutsatsen att traditionella medier i vissa fall kan ha en positiv relation till stödjande attityder och att sociala medier ansluter till några av de tveksamma åsikterna mot COVID-19.
Brandelid, Annie, and Evelina Eklund. "Tabloidization in Swedish news media? The ongoing pandemic in focus : A quantitative content analysis of how Swedish news media communicates about the COVID-19 vaccine." Thesis, Karlstads universitet, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:kau:diva-84600.
Повний текст джерелаI tider av kriser så som pandemier, krig eller naturkatastrofer ökar nyhetsmedias ansvar. Tidigare forskning har visat att människor i kris tenderar att söka efter information i traditionella medier för att hitta den mest pålitliga källan. Dessutom har dagens medielandskap stött på ett nytt paradigmskifte i form av digitalisering som har haft en vidsträckt påverkan på samhället och information är nu lättare tillgänglig för allmänheten. Som ett resultat kommer denna studie att undersöka den pågående COVID-19-pandemin med fokus på vaccination, som har fått mycket uppmärksamhet i media. Syftet med denna studie är att bidra med ny forskning genom att analysera hur Sveriges största morgontidning Dagens Nyheter och den största kvällstidningen Aftonbladet kommunicerat angående COVID-19-vaccinet. Studiens fyra forskningsfrågor syftar till att undersöka om det finns några skillnader eller likheter i hur Aftonbladet och Dagens Nyheter kommunicerat genom källkraft, tabloidisering och dimensioner från tidigare forskning: RQ1. Hur använder och nämner Aftonbladet och Dagens Nyheter källor i sina artiklar? RQ2. Hur är artiklarna i Aftonbladet och Dagens Nyheter utformade gällande fokusdimensioner (samhällelig eller individuell, episodisk eller tematisk)? RQ3. Hur är artiklarna i Aftonbladet och Dagens Nyheter utformade gällande stildimensioner (personlig eller opersonlig, känslomässig eller okänslomässig)? RQ4. Har artiklarna i Aftonbladet och Dagens Nyheter tendenser till tabloidisering baserat på innehåll och rubrik (positiv eller negativ, matchning mellan rubrik och text)? För att svara på de fyra frågorna har en kvantitativ innehållsanalys använts genom att analysera totalt 200 tidningsartiklar under en sexmånadersperiod. Med hjälp av verktyget Retriever har 100 artiklar från varje tidning valts ut genom ett obundet slumpmässigt urval. Med hjälp av det utformade kodschemat och kodboken har enheterna analyserats i SPSS. Det teoretiska ramverket bygger på journalistikens grundläggande principer, från händelse till nyheter, agenda-setting, framing och tabloidisering. Datan har analyserats, reflekteras och diskuteras med hjälp av teoretiska ramen samt tidigare forskning. Resultaten visar att de svenska medierna har kommunicerat med en hög grad av objektivitet, men att tabloidiseringen genomsyrar båda tidningar. Studiens viktigaste resultat visar bland annat att Dagens Nyheter, som enligt tidigare forskning tenderar att rapportera hårda nyheter, istället lutar mot en mer tabloidisering i sin nyhetsrapportering.
Aspenfjäll, Petra. "Antivaccinationsrörelsens avtryck i sociala medier." Thesis, Luleå tekniska universitet, Institutionen för ekonomi, teknik och samhälle, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:ltu:diva-85692.
Повний текст джерелаThe World Health Organization (WHO) has listed ten threats to the world health, two of which are pandemics and vaccine skepticism. Scientist agree that pandemics will affect humanity andat the same time people are being more skeptical about vaccine. Individuals who are critical of vaccine belongs to the anti-vaccination movement and believe that vaccines are a way of harming the population. The anti-vaccination movement use social media to spread their message. The ongoing pandemic is called covid-19 pandemic, vaccines have been developed in a short time and the population is offered the opportunity to be vaccinated. There are people who are critical of the vaccine and the restrictions that the government and the parliament hade decide about to reduce the spread of the SARS-CoV-2. The purpose of this study is to establish an understandig of how the work of the anti-vaccination movement is expressed on social media and how they act to influence people. The method for this study is netnography and it is used to study social and cultural contexts on the internet. To gather empirical data posts on Twitter have been studied through a non-participatory observation. Anthony Gidden’s concepts of trust and expert systems as well as Ulrich Beck’s concepts of the risk society have been used to analyze the posts. The results of this study show that individuals who express themselves negatively about vaccines have a low level of trust in the experts who are commenting about SARS-CoV-2 and they believe that vaccines are a way to control people. They believe that the restrictions that exist due to covid-19 pandemic are another way to restrict people’s freedom and that it was the big pharma that created the covid-19 pandemic. The anti-vaccination movement considered that the vaccine against the SARS-CoV-2 is more dangerous than the disease.
Hussein, Aida. "Inställning till vaccination mot covid- 19 i Rinkeby och Tensta, Sverige : Om vaccinationsvilja och tveksamhet i ett socioekonomiskt utsatt område i Sverige." Thesis, Högskolan i Skövde, Institutionen för hälsovetenskaper, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-20031.
Повний текст джерелаIntroduction: Vaccine hesitancy is a phenomenon that is important to study when the fight against covid-19 and other diseases is dependent on the population being vaccinated. Rinkeby-Tensta previously had low vaccination coverage due to concerns about side effects. The aim is to measure the attitude toward vaccination against covid -19 in Rinkeby-Tensta Method: A cross-sectional study was performed with convenience sample. Results: Results show that 72 respondents answered the survey, of which 78 percent of the respondents answered that they either do not want or do not know if they want to get vaccinated. Discussion: Level of education is not associated with willingness to get vaccinated. To postpone vaccinations is perceived as a benefit. Concerns about the side effects of vaccine is a factor in the vaccination decision.
Nyström, Elin, and Kajsa Söderberg. "Vuxnas erfarenheter och inställningar till att vaccinera sig : en litteraturstudie." Thesis, Luleå tekniska universitet, Institutionen för hälsa, lärande och teknik, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:ltu:diva-84129.
Повний текст джерелаHedlund, Simon, Philip Janols, and Glans Daniel Kling. "Aktieprisförändringar vid extrema händelser : Hur Pfizer och Modernas aktiekurser påverkades av pressmeddelanden rörande vaccinframtagningen för covid-19." Thesis, Högskolan Dalarna, Institutionen för kultur och samhälle, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:du-37647.
Повний текст джерелаUnder slutet av år 2019 började spridningen av coronaviruset SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2). Virussjukdomen, i folkmun känd som covid-19, började under år 2020 spridas från Kina till stora delar av övriga världen, vilket har resulterat i ett stort antal insjuknade, dödsfall och även en påverkan på såväl nationers som organisationers och individers ekonomi. För att begränsa spridningen av viruset påbörjade ett flertal läkemedelsbolag en vaccinframtagning. Denna process ledde till att läkemedelsbolagen kommunicerade en stor mängd bolagsnyheter till omvärlden, däribland investerare. Tidigare forskning har visat hur aktiemarknaden svarat på bolagsnyheter, men inför denna studie identifierades en brist på forskning kring hur aktiemarknaden agerar i förhållande till bolagsnyheter under extrema världssituationer likt coronaviruspandemin. Syftet med denna studie är att undersöka marknadens reaktion till följd av pressmeddelanden från företagen Moderna och Pfizer rörande vaccinutvecklingen för covid-19. Reaktionen studeras med hjälp av historiska aktiekursdata och beräkning av onormal avkastning. Resultaten har till en viss del indikerat på att utvalda pressmeddelanden har spelat en signifikant roll som påverkande faktor gentemot aktiemarknaden. Sett till resultatet i sin helhet är antalet signifikanta dagar inte tillräckligt för att utgöra stöd till alternativhypotesen. Marknadsreaktioner kunde identifieras till följd av pressmeddelanden om vaccinutvecklingen, men eftersom enbart 22 procent av den onormala avkastningen var signifikant så föreföll inte resultatet i linje med alternativhypotesen.
Wrywood, Sean. "Vaccin mot SARS-CoV-2 – en utvärdering av effektivitet och säkerhet av ledande vaccin : En Litteraturstudie." Thesis, Linnéuniversitetet, Institutionen för kemi och biomedicin (KOB), 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-104678.
Повний текст джерелаIntroduction: Coronaviruses are RNA viruses with a lipid envelope that is covered by characteristic spike protein. The most well-known coronaviruses are SARS-CoV-1 which were active between 2002-2004, MERS-CoV which is active since 2012 and SARS-CoV-2 which is active since 2019. SARS-CoV-2 was designated a pandemic January 30, 2020. Several pharmaceutical companies have been rushing to produce vaccines targeting SARS-CoV-2, The United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have had to issue Emergency Use Authorization (EUA) in the hope of gaining control of its spread. Objective: The purpose of this study is to investigate the safety and efficacy of the EMA-approved vaccines targeting SARS-CoV-2. Method: The studies for each vaccine were found and selected through the World Health Organizations' (WHO) "Draft landscape and tracker of COVID-19 candidate vaccines". A total of eight studies were included based on ten clinical trials examining the safety and efficacy of the four leading vaccines from Pfizer BioNTech, Moderna, AstraZeneca and Johnson & Johnson. Results: The four vaccines examined showed good safety without any serious side effects, the most common side effects with all vaccines were local pain, fatigue, and headache. These side effects lasted between one to two days after vaccination and were mostly mild. Larger differences could be seen in the efficacy of the different vaccines, with Pfizer BioNTech and Moderna's mRNA vaccines showing efficacies of around 95%. While AstraZeneca and Johnson & Johnson's adenovirus vector vaccines showed efficacies of around 66-70%. Discussion: No major differences in safety could be seen between the vaccines examined. AstraZeneca used an influenza vaccine instead of isotonic aqueous solution for their control groups, this may have had an impact on placebo and thus the results of their trials. A clear difference in efficacy could be seen between the different types of vaccines. This has a great influence on how easily one could induce herd immunity to a population. Herd immunity plays a major role in both slowing the spread but also in preventing the occurrence of new virus variants, therefore mRNA vaccines should be recommended if possible.
ALTAMIRA, Asociación Peruana de Bibliotecas Académicas. "Boletín diario de información científica N° 15." Asociación Peruana de Bibliotecas Académicas ALTAMIRA, 2020. http://hdl.handle.net/10757/651864.
Повний текст джерелаALTAMIRA, Asociación Peruana de Bibliotecas Académicas. "Boletín diario de información científica N° 26." Asociación Peruana de Bibliotecas Académicas ALTAMIRA, 2020. http://hdl.handle.net/10757/651935.
Повний текст джерелаWassbro, Sandra. "”I brist på vaccin har vi kommunikation” : Att skydda det mänskliga omdömet för att rädda liv under covid-19-infodemin." Thesis, Försvarshögskolan, 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:fhs:diva-9612.
Повний текст джерелаNilsonne, Ebba, and Christina Stareborn. "Alarm och turbulens sätter ramarna : En framinganalys av Svenska Dagbladet, Dagens Nyheter, Expressen och Aftonbladet nyhetsrapportering av Covid-19-vaccin under mars 2021." Thesis, Södertörns högskola, Institutionen för samhällsvetenskaper, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:sh:diva-46401.
Повний текст джерелаALTAMIRA, Asociación Peruana de Bibliotecas Académicas. "Boletín diario de información científica N° 14." Asociación Peruana de Bibliotecas Académicas ALTAMIRA, 2020. http://hdl.handle.net/10757/651857.
Повний текст джерелаKriström, Julia, and Louise Mannerfelt. "“Var är vaccinet mot våld i nära relationer?” : en komparativ innehållsanalys om svensk nyhetspress framställning av våld i nära relationer innan och under covid-19-pandemin." Thesis, Ersta Sköndal Bräcke högskola, Institutionen för socialvetenskap, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:esh:diva-8964.
Повний текст джерелаMurer, Bianca. "Emergenza e pandemia: Traduzioni dal sito web del Robert Koch Institut." Bachelor's thesis, Alma Mater Studiorum - Università di Bologna, 2021.
Знайти повний текст джерелаMartins, Tânia Daniela Ferreira. "Enquadramento regulamentar dos ensaios clínicos na Covid-19." Master's thesis, 2021. http://hdl.handle.net/10284/10501.
Повний текст джерелаThe severe acute respiratory syndrome, SARS-CoV-2, is a new coronavirus that was detected in China and suffered a rapid dissipation worldwide, making The World Health Organization declare a pandemic situation. This syndrome usually introduces symptoms such as fever, cough, fatigue and headache and, especially in old and high-risk patients, combined with other diseases, can develop into a more serious pathology with consequences mainly at the level of the respiratory tract, such as dyspnea and pneumonia. SARS-CoV-2 infection is transmitted between humans and the use of individual protection equipment and frequent hand hygiene are fundamental to prevent the transmission. There isn’t still scientific evidence of success to treat COVID-19, however the main measures adopted are the control of the symptoms carried out through basic and conventional therapies for the slightest symptoms. Drugs have been used in serious situations, they have shown positive effects as even as respiratory support in more critical cases. To return to normality before the pandemic situation (mainly in labor and social terms), the fast progress has become required in therapeutic and prophylactic measures such as the emergence of safe vaccines and following the achievement of a worldwide vaccination plan. During the medicine development until their introduction on the market, can last more than ten years to be commercialized. In the case of COVID-19, due to the activity worldwide scientific and monetary, it allowed the connection to development of the vaccine, in record time. In less than one year, the vaccine was developed and marketed following the mandatory standards, concerning the minimal effectiveness and without implicating their safety. In this literature review, multiple searches were carried out to certify the support regulation and dedicated efforts to achieve a safety vaccine to prevent SARS-CoV-2, in clinical trials. The results show a good tolerance, transparency and trust and all scientific communities and regulatory authorities are working accordingly.
Piçarra, Patricia Alexandra Jacinto. "Internship Reports and Monograph entitled "Virus-like particles based vaccines and their role in the COVID-19 pandemic”." Master's thesis, 2021. http://hdl.handle.net/10316/99021.
Повний текст джерелаEste trabalho de Final de Mestrado engloba os Relatórios de Estágio e Monografia Intitulada "Virus-like particles based vaccines and their role in the COVID-19 pandemic". No final de 2019, na China, um novo coronavírus foi identificado com o surgimento de uma pneumonia atípica. O mundo rapidamente ficou em alerta devido à alta velocidade com que este vírus se transmitia em todo o mundo. Este novo surto foi rapidamente declarado como uma pandemia.Desde o início surgiu a necessidade de criar uma vacina capaz de acabar com o pesadelo da pandemia.Diversas plataformas foram testadas para o desenvolvimento de vacinas contra a Síndrome Respiratória Aguda Grave Coronavirus 2 (SARS-COV-2), entre as quais vacinas que se baseiam em partículas semelhantes a vírus (VLP). As VLPs, que contam com alguns exemplos já existentes no mercado, como as vacinas para hepatite B e para o vírus do papiloma humano, são nanopartículas com base em proteínas que mimetizam a conformação do vírus, apresentando epítopos à superfície. As vacinas baseadas em VLPs já demonstraram ter inúmeras vantagens, incluindo o facto de serem seguras, não conterem o material genético do vírus e serem muito eficientes em termos de ativação do sistema imunológico. Apesar disso, na formulação destas vacinas muitas vezes aparecem associados adjuvantes.O conhecimento da estrutura do vírus SARS-COV-2 possibilitou o desenvolvimento de partículas que mimetizam este coronavírus.Pelo menos cinco vacinas de VLPs contra o SARS-COV-2 já estão em ensaios clínicos e apresentam potencial para serem bem-sucedidas.Neste texto de revisão, iremos reconhecer o potencial destas partículas que mimetizam os vírus, como elas ativam o nosso sistema imunológico, e desvendar os avanços que as vacinas baseadas em VLPs estão a ter nesta luta que o mundo está a enfrentar contra o COVID-19.Naturalmente, para isso temos que descobrir como funciona este vírus mortal.
This Master's Degree document comprises the Internship Reports and Monograph Entitled "Virus-like particles based vaccines and their role in the COVID-19 pandemic".In late 2019, in China, a new coronavirus was identified with the emergence of an atypical pneumonia. The world quickly became in alert due to the high speed with which this virus was being transmitted throughout the world. This new outbreak was quickly declared as a pandemic.From the outset the need arose to create a vaccine capable of putting an end to the pandemic nightmare.Several platforms were tested for the development of vaccines against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2), among which virus like particle (VLP) based vaccines. VLPs, with some examples already on the market such us the vaccines for the hepatitis B and for human papilloma virus, are protein-based nanoparticles that mimic the conformation of the virus, presenting epitopes on their surface. VLP based vaccines have already been shown to have numerous advantages, including the fact that they are safe, do not contain virus genetic material, and very efficient in terms of activating immune system. Despite that, in the formulation of these vaccines they often appear associated with adjuvants. The knowledge of the structure of the SARS-COV-2 has made it possible for the development of particles that mimic these coronavirus.At least, five SARS-COV-2 VLP vaccines are already in clinical trials, and show potential to be successful.In this review text we will recognize the potential of these particles that mimic viruses, and how they activate our immune system, and unravel the advances that VLP based vaccines are having in this fight that the world is facing with the COVID-19. Naturally, for that we have to find out how this deadly virus works.
Neto, Leila Maria Formiga. "Relatórios de Estágio e Monografia intitulada “Vacinas de mRNA: Novo paradigma na tecnologia de vacinas”." Master's thesis, 2021. http://hdl.handle.net/10316/98983.
Повний текст джерелаAs vacinas de ácidos nucleicos, que utilizam como plataforma um RNA mensageiro, codificam um antigénio essencial ao mecanismo de infeção do vírus, contra o qual desencadeiam uma resposta imunitária humoral e celular, que irá atuar rapidamente num futuro contacto com o vírus. A otimização da formulação, quer se trate da própria sequência de RNA, quer seja pela escolha de adjuvantes e, principalmente, pelo desenvolvimento de sistemas nanoparticulares que permitam a libertação controlada e proteção contra a degradação do mRNA, é essencial para promover uma resposta imunológica robusta. O ano de 2020 veio revolucionar o mundo da vacinação, com a aprovação de duas vacinas de mRNA em menos de um ano, após o início do seu desenvolvimento, a BNT162b2e a mRNA-1273. A necessidade de controlar a pandemia de COVID-19, impulsionou a aprovação destas vacinas, cujos resultados revelaram importantes vantagens em comparação com outras plataformas, nomeadamente, na tecnologia de produção de vacinas. A transcrição in vitro permite que a produção da vacina ocorra sem recurso a células, ovos ou bactérias, tornando-a mais célere e menos dispendiosa. Alguns dos desafios a ultrapassar passam por melhorar a estabilidade do mRNA, como desenvolvimento de novas estratégias, como a liofilização, que permitam facilitar o armazenamento das mesmas para condições menos exigentes de temperatura. Também o desenvolvimento de vacinas de mRNA para outras vias de administração, como a intranasal, será vantajoso por permitir a indução de uma resposta imunitária ao nível das mucosas. Com o desenvolvimento de processos padronizados para a criação de vacinas de mRNA, teoricamente, as indústrias farmacêuticas passam a ter a capacidade fabril de responder rapidamente a situações de emergência de saúde pública, causadas por novos agentes patogénicos ou novas variantes, para além de muitas outras aplicações que uma terapêutica à base de mRNA poderá ter. Nesta fase de comercialização das primeiras vacinas de mRNA, é importante manter a farmacovigilância sobre o produto, de modo a avaliar a imunogenicidade e segurança a longo prazo.
Nucleic acid vaccines, which use a messenger RNA as a platform, encode an antigen essential for the virus infection mechanism, against which they trigger a humoral and cellular immune response that will provide a quick action in a future contact with the virus. The optimization of the formulation, either by RNA sequence, or by addition of adjuvants and, mainly, by the development of delivery systems that allow a controlled release and protection against mRNA degradation, it is essential to promote a robust immune response. The 2020 year came to revolutionize the world of vaccination with the approval of two mRNA vaccines in less than a year after the beginning of their development, BNT162b2 e mRNA-1273. The need to control the exponential advance of the COVID-19 pandemic boosted the speed of approval of these vaccines and the results revealed important advantages, when compared to other platforms, especially in what concerns to vaccine production technology. In vitro transcription allows vaccines production without using cells, eggs or bacteria, making it faster and less expensive. Some of the challenges to be overcome include improving the stability of the mRNA, with the development of new strategies, such as lyophilization, which allow storage without demanding ultralow temperatures. Also, the development of mRNA vaccines for other routes of administration, such as intranasal, will be advantageous for allowing the induction of an immune response at the mucosal level. Through the development of standardized processes for the production of mRNA vaccines, theoretically, pharmaceutical industries now have the manufacturing capacity to respond quickly to public health emergencies caused by new pathogens or variants, in addition to many other applications that a mRNA-based therapy have. At this commercialization phase of the first mRNA vaccines, it is important to maintain the pharmacovigilance in order to assess its long-term immunogenicity and safety.
Almendra, Marta Inês Rabaçal. "Relatórios de Estágio e Monografia intitulada "Registo de medicamentos no EEE: Autorização das vacinas contra a COVID-19"." Master's thesis, 2021. http://hdl.handle.net/10316/99158.
Повний текст джерелаThis document was written as part of the curricular unit "Internship" of the Integrated Master's Degree in Pharmaceutical Sciences of the Faculty of Pharmacy of the University of Coimbra.The document includes three parts: two internship reports and a monograph. The first part refers to the internship in Community Pharmacy, at Farmácia do Altinho. The second part comprises the report of the internship in Regulatory Affairs and Pharmacovigilance, at PhaRegistrum - Consultoria Farmacêutica e Técnica, Lda. Both reports are presented in the format of a SWOT analysis, describing the Strengths, Weaknesses, Opportunities and Threats identified throughout the internship period. Finally, in the third part, this document includes the Monograph entitled "Registration of medicines in the EEA: Authorisation of COVID-19 vaccines". Proceeding to a brief summary of the monograph: A medicine can only be commercialised in the European Union (EU) when a Marketing Authorisation (MA) has been issued by the competent authority of a Member State or by the European Medicines Agency (EMA). In this last case, medicines are authorised through a Centralised Procedure, which results in a single MA valid for the entire EU market.The Centralised Procedure is mandatory, for example, in case of public health emergencies, such as the current pandemic of COVID-19, for the authorisation of promising medicines and vaccines. However, in such an emergency situation, it is necessary to expedite the processes and reduce the timelines for the evaluation and approval of medicines. Several regulatory agencies have mechanisms in place to authorise medicines for emergency situations, using accelerated review and approval pathways. At the same time, they maintain high standards of quality, efficacy and safety, ensuring that medicines are approved only after scientific evaluation has shown that their benefits outweigh their risks. In addition, for the COVID-19 vaccines, there is an extra resource mobilisation to assist in safety monitoring and risk management during vaccination campaigns. The main objective of this monograph is to describe how medicines are registered in the European Economic Area (EEA), focusing on accelerated assessment and approval of the COVID-19 vaccines, as well as their post-marketing monitoring. Some regulatory pathways through which these vaccines have been receiving fast-track approval by several regulatory agencies outside the EU will also be addressed.
Este documento foi redigido no âmbito da Unidade Curricular “Estágio” do Mestrado Integrado em Ciências Farmacêuticas, da Faculdade de Farmácia da Universidade de Coimbra.O documento é constituído por três partes: dois relatórios de estágio e uma monografia. A primeira parte é referente ao estágio em Farmácia Comunitária, na Farmácia do Altinho. Na segunda parte, é apresentado o relatório do estágio em Assuntos Regulamentares e Farmacovigilância, realizado na PhaRegistrum - Consultoria Farmacêutica e Técnica, Lda. Ambos os relatórios são apresentados sob a forma de uma análise SWOT, onde são descritos os Pontos Fortes, os Pontos Fracos, as Oportunidades e as Ameaças identificados no decorrer dos estágios. Por último, na terceira parte, este documento inclui a Monografia intitulada “Registo de medicamentos no EEE: Autorização das vacinas contra a COVID-19”. Passando a uma breve síntese da monografia: Um medicamento só pode ser comercializado na União Europeia (UE) quando uma Autorização de Introdução no Mercado (AIM) tiver sido emitida pela autoridade competente de um Estado-Membro ou pela Agência Europeia de Medicamentos (EMA). Neste último caso, os medicamentos são autorizados através de um Procedimento Centralizado, que resulta numa única AIM válida para todo o mercado da UE.O Procedimento Centralizado é obrigatório, por exemplo, perante emergências de saúde pública, como a atual pandemia de COVID-19, para a autorização de medicamentos e vacinas promissores. No entanto, em tal situação de emergência, torna-se necessário agilizar os processos e reduzir os prazos de avaliação e aprovação dos medicamentos. Diversas agências reguladoras dispõem de mecanismos de autorização de medicamentos para situações de emergência, utilizando vias de revisão e de aprovação aceleradas. Ao mesmo tempo, estas mantêm elevados padrões de qualidade, eficácia e segurança, assegurando que os medicamentos apenas são aprovados depois de uma avaliação científica ter demonstrado que os seus benefícios superam os seus riscos. Para além disso, para as vacinas contra a COVID-19, existe uma mobilização de recursos extra para auxiliar na monitorização da segurança e na gestão de riscos durante as campanhas de vacinação. Esta monografia tem como principal objetivo descrever de que forma os medicamentos são registados no Espaço Económico Europeu (EEE), com foco na avaliação e aprovação aceleradas das vacinas contra a COVID-19, bem como na sua monitorização pós-comercialização. Serão, também, abordadas algumas vias regulatórias através das quais estas vacinas têm obtido aprovação rápida por diversas agências reguladoras fora da UE.
Macedo, Patrícia Isabel Nunes. "Relatório de Estágio e Monografia intitulada " A inovação farmacêutica e o desenvolvimento de vacinas: o caso da COVID-19"." Master's thesis, 2021. http://hdl.handle.net/10316/99008.
Повний текст джерелаO plano curricular do Mestrado Integrado em Ciências Farmacêuticas (MICF) contempla um conteúdo programático muito completo, que integra todo o ciclo do medicamento. Na fase final do curso, os conhecimentos teóricos são aplicados à prática através de um estágio curricular em Farmácia Comunitária ou ainda um segundo estágio facultativo em Farmácia Hospitalar ou em Indústria Farmacêutica.Neste sentido, realizei o estágio curricular na Bluepharma, uma Indústria Farmacêutica portuguesa, e na Farmácia dos Olivais, ambos em Coimbra. Estas duas experiências profissionais estão descritas no presente relatório, através de uma análise SWOT. A monografia também está presente neste trabalho, intitulada de “A inovação farmacêutica e o desenvolvimento de vacinas: o caso da COVID-19”. A inovação farmacêutica representa um grande valor social e económico para a sociedade e é fulcral para qualquer sistema de saúde da atualidade. A geração de inovação é a chave da IF, que tem um papel fundamental no desenvolvimento de novos medicamentos, vacinas e tratamentos capazes de transformar a vida da população. A IF tem contribuído para o aumento da qualidade e da esperança média de vida. As vacinas têm grande impacto na saúde pública e são uma das tecnologias mais eficazes e económicas no combate a doenças infeciosas. Ao longo dos anos, têm ocorrido surtos de doenças infeciosas - SARS, gripe H1N1, MERS, Ébola, Zika, febre de Lassa, entre outros – que são fortes indícios da falta de preparação de uma resposta a epidemias que requereriam um rápido desenvolvimento e distribuição de vacinas a nível mundial. Com a situação pandémica da COVID-19, renasceu o interesse pelo desenvolvimento de estratégias de I&D para prevenir, tratar e controlar estes vírus. Um conjunto de vários fatores contribuiu para a evolução do ecossistema de inovação e desenvolvimento de vacinas seguras e eficazes a um ritmo sem precedentes. Apesar de o mundo não estar preparado para esta emergência de saúde pública, a COVID-19 trouxe grandes mudanças nos investimentos em doenças infeciosas, desenvolvimento de medicamentos e programas regulamentares. No futuro, será fundamental garantir um ecossistema de inovação sustentável. A humanidade terá de estar pronta responder a estas ameaças globais à saúde, reduzindo o seu impacto na população.
The curricular plan of the Integrated Master’s in Pharmaceutical Sciences (MICF) includes a very complete program, which integrates the entire medicine cycle. In the final stage of the course, theoretical knowledge is applied to practice through a curricular internship in Community Pharmacy or a second optional internship in Hospital Pharmacy or Pharmaceutical Industry.In this sense, I did an internship at Bluepharma, a Portuguese Pharmaceutical Industry, and at Farmácia dos Olivais, both in Coimbra. These two professional experiences are described in this report, through a SWOT analysis. The monograph is also present in this work, entitled “Pharmaceutical innovation and vaccine development: the case of COVID-19”. Pharmaceutical innovation represents a great social and economic value for society and is central to any healthcare system today. Generating innovation is the key to IF, which has a fundamental role in the development of new drugs, vaccines and treatments capable of transforming the lives of the population. The IF has contributed to the increase in quality and average life expectancy. Vaccines have a major impact on public health and are one of the most effective and affordable technologies to fight infectious diseases. Over the years, outbreaks of this diseases have occurred - SARS, H1N1 flu, MERS, Ebola, Zika, Lassa fever, among others. These are strong indications of the lack of preparation for an epidemic response, that would require rapid development and worldwide vaccine distribution. With the pandemic situation of COVID-19, interest in the development of R&D strategies to prevent, treat and control these viruses was reborn. Several factors have contributed to the evolution of the ecosystem of innovation and development, of safe and effective vaccines, at an unprecedented pace. Although the world is unprepared for this public health emergency, COVID-19 has brought major changes in investments in infectious diseases, drug development, and regulatory programs. In the future, it will be essential to ensure a sustainable innovation ecosystem. Humanity will have to be ready to respond to these global health threats, reducing their impact on the population
Winkler, Noni. "Investigating vaccine preventable diseases and the COVID-19 pandemic." Master's thesis, 2022. http://hdl.handle.net/1885/265413.
Повний текст джерелаHenriques, Daniela Filipa da Conceição. "BCG Vaccine for Immune-prophylaxis during the Pandemic of COVID-19: a systematic review." Master's thesis, 2021. http://hdl.handle.net/10316/98498.
Повний текст джерелаABSTRACT:Introdução:Desde que o vírus da Síndrome Respiratória Aguda Grave (SARS-CoV-2) surgiu na China no final de 2019, infectou mais de 93 milhões de humanos em todo o mundo, sobrecarregando os sistemas de saúde e causando mais de 2 milhões de mortes. A fácil propagação do vírus e a necessidade de proteção dos profissionais de saúde chamaram a atenção para a vacina Bacillus Calmette-Guérin (BCG). O BCG é conhecido por efeitos não específicos na melhoria da imunidade inata. Algumas estudos sugeriram eventual proteção contra o coronavírus em nações onde o BCG faz parte da política nacional de vacinação.Métodos:Após o registro do protocolo no PROSPERO (ID = CRD42020188486), realizamos uma revisão sistemática da literatura nos bancos de dados PubMed, EMBASE, Web of Science, Clinical Trials.gov e Cochrane Library sobre o uso da vacina BCG para imunoprofilaxia de SARS-CoV-2. Uma pesquisa adicional foi realizada no MedRxiv para pre-prints. A seleção dos manuscritos foi realizada de acordo com as diretrizes PRISMA. O papel da vacinação BCG foi avaliado em termos de incidência e gravidade da doença COVID-19.Resultados:453 resumos foram inicialmente revistos e recuperados 76 artigos com texto completo. Destes, 51 estudos preencheram os critérios de inclusão: 36 artigos originais e 15 ensaios clínicos.Verificou-se efeito positivo da vacina BCG na diminuição dos casos de COVID-19 e na mortalidade por COVID-19. Os indivíduos vacinados com BCG são menos propensos a contrair a doença do que os não vacinados, geralmente são assintomáticos e têm menor probabilidade de serem hospitalizados durante o curso da doença.Conclusões:Estudos epidemiológicos e de coorte sugerem que a vacinação BCG pode prevenir o COVID-19, porém sem uma avaliação mais cuidadosa e detalhada não podemos assumir isso como evidência irrefutável.
Background: Since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus emerged in China by the end of 2019, it has infected more than 93 million humans around the world, overwhelmed health systems worldwide and caused more than 2 million deaths. The easy-spread of the virus and the need for health care professional’s protection raised attention to Bacillus Calmette-Guérin (BCG) vaccine. BCG is known for nonspecific, protective innate immune–boosting effects.Early evidence suggested eventual protection against coronavirus in nations where BCG is part of the national vaccination policy. Methods: After a priori protocol registration in PROSPERO(ID=CRD42020188486), we performed a systematic literature review in PubMed, EMBASE, Web of Science, Clinical Trials.gov and Cochrane Library databases for studies on the use BCG Vaccine for immune- prophylaxis of SARS-CoV illness. Further search was also performed on MedRxiv for pre-prints. Manuscripts selection was conducted according to PRISMA guidelines. The role of BCG vaccination was assessed in terms of incidence and severity of COVID-19 disease. Results: 453 abstracts were initially reviewed and 76 full-text articles were retrieved. From those, 51 studies met the inclusion criteria: 36 original articles and 15 clinical trials. A positive effect of the BCG vaccine on diminishing COVID-19 cases and mortality was verified. Individuals that underwent BCG vaccination are less likely to contract the disease than unvaccinated, are usually asymptomatic and have a lower probability to be hospitalized during the disease course. Conclusions: Epidemiological and cohort studies suggest that BCG vaccination might prevent COVID-19, however without a thoughtful and more detailed evaluation we cannot assume this as irrefutable evidence.
Alsulami, Abdulrahman Fahim M. "The Impact of Bilateral Investment Treaties on Health-related Intellectual Property Rights in the TRIPS Agreement." Thesis, 2021. https://vuir.vu.edu.au/43471/.
Повний текст джерелаÅkra, Gisle Røe. "The COVID-19 vaccine race, government bond yields, and index futures : analysis of 34 OECD member countries." Master's thesis, 2021. http://hdl.handle.net/10400.14/35736.
Повний текст джерелаEsta dissertação tem o objetivo de investigar como os rendimentos de títulos públicos de 34 países-membro da OECD, mais cinco índices de futuros, reagiram aos anúncios das vacinas para a COVID-19 Moderna Inc. e Pfizer Inc./BioNTech durante 2020. O método de estudo de evento e retornos anormais (cumulativos) é usado como ferramenta essencial para investigar os impactos. Eu descobri que o anúncio da fase 3 da Pfizer em Novembro 2020 foi o evento que gerou os resultados mais significativos em rendimentos de títulos públicos e índices de futuros juntos, em termos de retornos anormais cumulativos e estimativas de regressão do evento. Contudo, o anúncio em Maio 2020 da fase 1 da vacina Moderna teve impactos significativos no otimismo económico, que é refletido em retornos anormais cumulativos dos índices de futuros e das estimativas de regressão do respetivo evento. Adicionalmente, investiguei outras variáveis económicas e da COVID-19 para compreender os determinantes dos rendimentos anormais das obrigações. Eu descobri que emprestar/pedir emprestado líquido em % do PIB, inflação e taxas de desemprego são em geral as variáveis com maior significância.
Martins, Mara Daniela Da Rocha. "Covid-19: the impact on the hotel industry - the Nh hotel group case study." Master's thesis, 2020. http://hdl.handle.net/10362/122675.
Повний текст джерелаSimões, Patrícia Sofia Francisco. "Intenção de vacinação contra a COVID-19 em Portugal : preditores sociodemográficos e psicossociais." Master's thesis, 2021. http://hdl.handle.net/10400.14/37013.
Повний текст джерелаVaccination is one of the fundamental measures taken to control the pandemic due to COVID-19, which makes it important to comprehend the predictors of the intention of getting vaccinated, in order to promote its adherence. This study had the goal to evaluate the intention to get vaccinated in a sample of Portuguese individuals, as well as explore an ensemble of sociodemographic and psychosocial variables, based on three predictive models (i.e., Health Belief Model, Theory of Planned Behavior, and the 3 C’s Model), as predictors of said intention. Additionally, it was intended to understand if the news about adverse reactions and suspension of the vaccination program with one of the vaccine brands might have had impact on the trust on vaccines and intentions to get vaccinated. This study was transversal, quantitative, with data collected through an online questionnaire. The sample consisted of 383 participants, living in Portugal that, until the date, were not vaccinated against COVID-19. The results showed that the intention to get vaccinated was higher in people with other nationality non-Portuguese, in between health professionals, that lived with people above 65 years old. The psychosocial determinants that were associated with the intention to get vaccinated were skepticism, with a negative relation, understood benefits, social norm, and risk perception (susceptibility), all with positive relations considering intention to get vaccinated. After the emerging news on the media about the possible adverse effects associated to AstraZeneca, it was observed a decrease in the intention to get vaccinated and trust towards all vaccines, especially AstraZeneca. These results contribute to the identification of target groups that should be prioritized when intervening, as well as what beliefs and predictors potentially modified can be used to promote adherence to vaccination.
AJOVALASIT, Samantha. "Disorientation towards routine immunization, COVID-19 anxiety, and propensity to vaccinate. An analysis based on Twitter data in Italy." Doctoral thesis, 2020. http://hdl.handle.net/11570/3182147.
Повний текст джерелаJesus, Ana Rita Moreira Gaspar de. "O Processo de Desenvolvimento e Aprovação de Medicamentos: O Caso Particular das Vacinas COVID-19." Master's thesis, 2021. http://hdl.handle.net/10316/99135.
Повний текст джерелаUm novo medicamento está sujeito a um rigoroso processo de investigação, desenvolvimento, avaliação e aprovação, por forma a garantir a sua qualidade, segurança e eficácia e o cumprimento dos requisitos exigidos pelas entidades regulamentares competente. No final do ano de 2019, foi identificado um novo coronavírus, o SARS-CoV-2. Este agente etiológico, causador da doença COVID-19, rapidamente se disseminou por todo o mundo, levando a Organização Mundial de Saúde (OMS) a decretar o estado de pandemia COVID-19, a 11 de março de 2020. A situação de emergência gerada, desafiou os sistemas de saúde e as autoridades competentes a nível mundial, exigindo a afetação excecional de recursos técnicos, financeiros e humanos, por forma a combater a crise de saúde pública instalada. O desenvolvimento de uma vacina eficaz contra a COVID-19, foi identificada como a melhor estratégia para suster a pandemia, levando à adoção de estratégias diferenciadas e da convergência de esforços por forma a acelerar o processo de desenvolvimento e introdução no mercado de vacinas contra a COVID-19. Neste estudo pretende-se analisar como decorreu o processo de introdução no mercado das vacinas COVID-19. Serão abordadas as especificidades regulamentares que foram adotadas de modo a permitir a célere aprovação e comercialização destas vacinas.
A new drug is subject to a rigorous research, development, evaluation, and approval process to ensure the quality, safety and efficacy of the drug and compliance with the requirements of the relevant regulatory authorities. Late in 2019, a new coronavirus, SARS-CoV-2, was identified. This etiological agent, causing the disease COVID-19, quickly spread throughout the world, leading the World Health Organization (WHO) to decree the state of pandemic COVID-19, on March 11, 2020.This emergency has challenged health systems and competent authorities worldwide, requiring the exceptional allocation of technical, financial, and human resources to combat the public health crisis. The development of an effective vaccine against COVID-19 was identified as the best strategy to halt the pandemic, leading to the adoption of differentiated strategies and the convergence of efforts to accelerate the process of development and market introduction of vaccines against COVID-19. This study aims to analyze how the market introduction process of the COVID-19 vaccines took place. The regulatory specificities that were adopted to allow the rapid approval and marketing of these vaccines will be addressed.
SANTIROCCHI, ALESSANDRO. "Psycho-cognitive predictors of risk perception, social distancing and vaccination intention during COVID-19 outbreak: the case of Italy." Doctoral thesis, 2022. http://hdl.handle.net/11573/1651050.
Повний текст джерелаBranco, Filipa Saraiva e. Silva Rodrigues. "Influência e caracterização do movimento antivacinação nas redes sociais em Portugal." Master's thesis, 2021. http://hdl.handle.net/10362/131416.
Повний текст джерелаBackground: The pandemic by SARS-CoV-2 virus and the vaccines developed will face obstacles created by the dissemination of fake news and conspiracies propagated by the anti-vaccination movement on social media. Thus, the vaccine hesitation will have contours never seen before, in Portugal. Methods: This study analyzes the posts, comments, and members of the Facebook group “Anti-VAX Portugal” from April 10th to October 10th, during the pandemic. As well as the development of an online questionnaire survey where we understand the influence that anti-vaccination content has on social media users to take the COVID-19 vaccine. Results: The analysis of 347 members, with different motivations, culminates in 440 publications where 48% are conspiracy theories. Vaccine sharing for COVID-19 started long before there was one. In the online survey, we verified that the influence of anti-vaccination content on social media, on hesitant individuals, is four times higher than if they had not come across such content. Also, for those who have already decided that they will not be vaccinated against the SARS-CoV-2 virus, more than half were exposed to the contents of the anti-vaccination movement. Conclusion: This movement is highly capable of influencing the opinion of others through anti-vaccination campaigns, carried out before the creation of the vaccine for COVID-19 and social media is the ideal vehicle for the dissemination and organization of actions outside the digital space.